Navigation Links
Savient Pharmaceuticals to Present at the Cowen and Company 32nd Annual Health Care Conference
Date:2/23/2012

EAST BRUNSWICK, N.J., Feb. 23, 2012 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today announced that Kenneth Zuerblis, Executive Vice President and Chief Financial Officer of Savient will present at the Cowen and Company 32nd Annual Health Care Conference on Tuesday, March 6, 2012 at 10:40 AM Eastern Time.  The conference will be held at the Boston Marriott Copley Place in Boston, MA.

A live webcast of the presentation can be accessed through the investor relations section of the Company's website at www.savient.com.  Following the live presentation, a replay of the webcast will be available on the Company's website for 30 days.

ABOUT SAVIENT PHARMACEUTICALS, INC.Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP").  Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA.  Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S. For more information, please visit the Company's website at www.savient.com.Contact:  Mary Coleman Carney Noensie Savient Pharmaceuticals, Inc. Burns McClellan information@savient.com  cnoensie@burnsmc.com (732) 418-9300  (212) 213-0006SVNT - G


'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Pharmaceuticals to Present at the Citi 2012 Global Health Care Conference
2. Savient Pharmaceuticals Appoints David Y. Norton Interim Chief Executive Officer
3. Savient Pharmaceuticals Appoints Experienced Pharmaceutical Executive, David Veitch as President of Savient Europe
4. Savient Pharmaceuticals Announces Permanent J-Code Assigned for KRYSTEXXA®
5. Savient Pharmaceuticals to Present at the Noble Financial Capital Markets Eighth Annual Equity Conference
6. Savient Pharmaceuticals Announces New Data Surrounding KRYSTEXXA® and the Impact of Refractory Chronic Gout at the American College of Rheumatology Meeting
7. Savient Pharmaceuticals Reports Third Quarter 2011 Financial Results
8. Savient Pharmaceuticals to Hold Third Quarter 2011 Financial Results Conference Call on Thursday, November 3, 2011
9. Savient Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference
10. Savient Pharmaceuticals Names Kenneth J. Zuerblis Chief Financial Officer
11. Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2017)... May 4, 2017  A new tight-tolerance microextrusion ... other highly-engineered materials, is being launched by Natvar, ... been developed in recent years to service a ... surgical applications. More expensive materials such as glass ... tubing due to their ability to consistently hold ...
(Date:5/3/2017)... 2017  Kalorama Information notes that transplant diagnostics ... year and this is projected to continue to ... (HSCT) or bone marrow transplants require histocompatibility between ... for this task. This according to a new ... The various PCR-based methodologies, Sanger sequencing and NGS ...
(Date:5/2/2017)... and NEW YORK ... As the leading distributor of market intelligence, ... European Med Tech Reimbursement Consulting AB that ... Tech Reimbursement Consulting AB,s proprietary market analyses through the ... professionals around the world easy access to complete product ...
Breaking Medicine Technology:
(Date:5/23/2017)... , ... May 23, 2017 , ... ... North Carolina have remained steady since 2009, according to a Workers Compensation Research ... The study Monitoring the North Carolina System: CompScope™ Benchmarks, 17th Edition ...
(Date:5/23/2017)... ... May 23, 2017 , ... ... and a 2017 Best in KLAS category winner, has named Daniel P. Bullington ... extend and enhance its technology platform and product offerings,” says Justin Neece, president. ...
(Date:5/23/2017)... ... , ... London, May 23, 2017: Walter Schindler, the Founder and Managing Partner ... Speaker and Contributor to a weeklong series of classes, meetings, field trips and special ... Walter Schindler and SAIL Capital have received an increasing number of ...
(Date:5/23/2017)... ... May 23, 2017 , ... By all indications, and due to months of ... call for diligence, asking homeowners to scout for any open water sources that can ... the annoying buzz of mosquitos is the buzz associated with potential infections stemming from ...
(Date:5/23/2017)... ... May 23, 2017 , ... MedTech For Solutions has announced ... laboratory, to provide hands-on training utilizing cutting-edge equipment at its recently-opened OvaTools Andrology ... MedTech Group Purchasing vendor , will provide specialized equipment to ensure OvaTools participants ...
Breaking Medicine News(10 mins):